dlt446 dlt446

dlt446 dlt446

Clinical Professor

Member of:

  • Neurology


Publication year:
All
76 - 100 out of 374Page size: 25
Sort by: 1st author
  1. Published

    Human models of migraine: short-term pain for long-term gain

    dlt446, dlt446, Hansen, J. M., Á Dunga, B. O. & Olesen, Jes, Dec 2017, In: Nature Reviews. Neurology. 13, p. 713-724 12 p.

    Research output: Contribution to journal › Review › Research › peer-review

  2. Published

    Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

    dlt446, dlt446, Saper, J., Cady, R., Schaeffler, B. A., Biondi, D. M., Hirman, J., Pederson, S., Allan, B. & Smith, J., Mar 2020, In: Cephalalgia : an international journal of headache. 40, 3, p. 241-254 14 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Migraine

    dlt446, dlt446, 2020, In: New England Journal of Medicine. 383, 19, p. 1866-1876 11 p.

    Research output: Contribution to journal › Review › Research › peer-review

  4. Published

    Lack of correlation between vasodilatation and pharmacologically induced immediate headache in healthy subjects

    dlt446, dlt446, Tfelt-Hansen, P., Dalgaard, P. & Olesen, Jes, 2011, In: Cephalalgia. 31, 6, p. 683-90 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

    dlt446, dlt446, Cohen, J. M., Galic, M., Campos, V. R., Barash, S., Ning, X., Kessler, Y., Janka, L. & Diener, H. C., 2021, In: Journal of Headache and Pain. 22, 68.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial

    dlt446, dlt446, Tepper, S. J., Reuter, U., Blumenfeld, A. M., Hutchinson, S., Xia, J., Miceli, R., Severt, L., Finnegan, M. & Trugman, J. M., 2023, In: Headache. 63, 1, p. 79-88 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    PEARL study protocol: A real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

    dlt446, dlt446, Amin, Faisal Mohammad, Kokturk, P., Cohen, J. M., Konings, M., Tassorelli, C., Lyras, L. & Mitsikostas, D. D., 2021, In: Pain Management. 11, 6, p. 647-654

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Pearls and pitfalls in human pharmacological models of migraine: 30 years' experience

    dlt446, dlt446, Hansen, J. M. & Olesen, Jes, Jun 2013, In: Cephalalgia. 33, 8, p. 540-53 14 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study

    dlt446, dlt446, Dodick, D., Goadsby, P. J., Reuter, U., Silberstein, S., Zhang, F., Gage, J. R., Cheng, S., Mikol, D. D. & Lenz, R. A., 19 Sep 2017, In: Neurology. 89, 12, p. 1237-1243 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis

    dlt446, dlt446, Tepper, S. J., Brandes, J. L., Reuter, U., Boudreau, G. P., Weatherall, M., Gantenbein, A. R., Doležil, D., Klatt, J., Wang, A., Karanam, A. K., Cheng, S. & Mikol, D., 2022, In: Headache. 62, 5, p. 624-633 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  11. Published

    Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions

    dlt446, dlt446, Kudrow, D., Reuter, U., Dolezil, D., Silberstein, S., Tepper, S. J., Xue, F., Picard, H., Zhang, F., Wang, A., Zhou, Y., Hong, F., Klatt, J. & Mikol, D. D., Dec 2019, In: Cephalalgia. 39, 14, p. 1798-1808

    Research output: Contribution to journal › Journal article › Research › peer-review

  12. Published

    Vascular changes have a primary role in migraine

    dlt446, dlt446, 2012, In: Cephalalgia. 32, 5, p. 428-30 3 p.

    Research output: Contribution to journal › Comment/debate › Research › peer-review

  13. Published

    Assessment of Erenumab Safety and Efficacy in Patients with Migraine with and Without Aura: A Secondary Analysis of Randomized Clinical Trials

    dlt446, dlt446, Goadsby, P. J., Dodick, D. W., Tepper, S. J., Xue, F., Zhang, F., Brennan, F. & Paiva Da Silva Lima, G., Feb 2022, In: JAMA Neurology. 79, 2, p. 159-168 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  14. Published

    Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside

    dlt446, dlt446, Hoffmann, J., Ashina, H., Hay, D. L., Flores-Montanez, Y., Do, T. P., De Icco, R. & Dodick, D. W., 2024, In: Mayo Clinic Proceedings. 99, 2, p. 285-299 15 p.

    Research output: Contribution to journal › Review › Research › peer-review

  15. Published

    Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study

    dlt446, dlt446, Mitsikostas, D. D., Amin, Faisal Mohammad, Kokturk, P., Schankin, C. J., Sahin, G., Pozo-Rosich, P., Dorman, P. J., Nežádal, T., Poole, A. C., Martins, I. P., Sumelahti, M. L., Ramirez Campos, V., Ahn, A. H., Lyras, L. & Tassorelli, C., 2023, In: Cephalalgia. 43, 11, 12 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  16. Published

    Migraine: disease characterisation, biomarkers, and precision medicine

    dlt446, dlt446, Terwindt, G. M., Al-Karagholi, M. A. M., de Boer, I., Lee, M. J., Hay, D. L., Schulte, L. H., Hadjikhani, N., Sinclair, A. J., Ashina, H., Schwedt, T. J. & Goadsby, P. J., 17 Apr 2021, In: The Lancet. 397, 10283, p. 1496-1504 9 p.

    Research output: Contribution to journal › Review › Research › peer-review

  17. Published

    The most important advances in headache research in 2018

    dlt446, dlt446, 2019, In: Lancet Neurology. 18, 1, p. 5-6

    Research output: Contribution to journal › Comment/debate › Research

  18. Published

    Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

    dlt446, dlt446, Tepper, S., Brandes, J. L., Reuter, U., Boudreau, G., Dolezil, D., Cheng, S., Zhang, F., Lenz, R., Klatt, J. & Mikol, D. D., 1 Sep 2018, In: Cephalalgia. 38, 10, p. 1611-1621 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  19. Published

    Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2

    dlt446, dlt446, McAllister, P., Cady, R., Hirman, J. & Ettrup, A., 2022, In: Cephalalgia. 42, 8, p. 696-704 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  20. Published

    Migraine: epidemiology and systems of care

    dlt446, dlt446, Katsarava, Z., Do, T. P., Buse, D. C., Pozo-Rosich, P., Özge, A., Krymchantowski, A. V., Lebedeva, E. R., Ravishankar, K., Yu, S., Sacco, S., Ashina, Sait, Younis, S., Steiner, T. J. & Lipton, R. B., 17 Apr 2021, In: The Lancet. 397, 10283, p. 1485-1495 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  21. Published

    Board Walk – April 2021

    dlt446, dlt446 & Katsarava, Z., 2021, In: Cephalalgia. 41, 5, p. 634-636 3 p.

    Research output: Contribution to journal › Editorial › Research › peer-review

  22. Published

    A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention

    dlt446, dlt446, Doležil, D., Bonner, J. H., Zhou, L., Klatt, J., Picard, H. & Mikol, D. D., 2021, In: Cephalalgia. 41, 1, p. 33-44 12 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  23. Published

    Neurovascular origin of primary headaches

    dlt446, dlt446 & Ayata, C., Apr 2019, In: Journal of Cerebral Blood Flow and Metabolism. 39, 4, p. 571-572

    Research output: Contribution to journal › Editorial › Research › peer-review

  24. Published

    Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies

    dlt446, dlt446, Vasudeva, R., Jin, L., Lombard, L., Gray, E., Doty, E. G., Yunes-Medina, L., Kinchen, K. S. & Tassorelli, C., 2019, In: Headache. 59, 10, p. 1788-1801

    Research output: Contribution to journal › Journal article › Research › peer-review

  25. Published

    Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine

    dlt446, dlt446, Goadsby, P. J., Reuter, U., Silberstein, S., Dodick, D., Rippon, G. A., Klatt, J., Xue, F., Chia, V., Zhang, F., Cheng, S. & Mikol, D. D., Oct 2019, In: Cephalalgia. 39, 11, p. 1455-1464

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1 2 3 4 5 6 7 8 ...15 Next

ID: 920785